Who are PLB1001's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Wayrilz, Hernexeos, Romvimza, Itovebi, Itovebi, Ojemda.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/plb1001.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

PLB1001 — Competitive Intelligence Brief

PLB1001 (PLB1001) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase inhibitor. Area: Oncology.

phase 3 Kinase inhibitor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PLB1001 (PLB1001) — Beijing Pearl Biotechnology Limited Liability Company. PLB1001 is a small-molecule inhibitor that targets specific kinases involved in cancer cell proliferation and survival.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PLB1001 TARGET	PLB1001	Beijing Pearl Biotechnology Limited Liability Company	phase 3	Kinase inhibitor
Wayrilz	RILZABRUTINIB	Genzyme Corp	marketed	Kinase Inhibitor [EPC]		2025-01-01
Hernexeos	ZONGERTINIB	Boehringer Ingelheim	marketed	Kinase Inhibitor [EPC]		2025-01-01
Romvimza	VIMSELTINIB	Deciphera Pharms	marketed	Kinase Inhibitor [EPC]		2025-01-01
Itovebi	INAVOLISIB	Genentech Inc	marketed	Kinase Inhibitor [EPC]		2025-01-01
Itovebi	inavolisib	Pfizer	marketed	Kinase Inhibitor [EPC]	phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)	2024-01-01
Ojemda	TOVORAFENIB	Day One Biopharms	marketed	Kinase Inhibitor [EPC]		2024-01-01

Recent regulatory actions (last 90 days)

2026-02-26 — Hernexeos · FDA · approved · US · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase inhibitor class)

Beijing Pearl Biotechnology Limited Liability Company · 1 drug in this class
Eli Lilly · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PLB1001 — Competitive Intelligence Brief. https://druglandscape.com/ci/plb1001. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab